Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study

2019 ◽  
Vol 38 (1) ◽  
pp. 211-218 ◽  
Author(s):  
Hayato Kawachi ◽  
Motohiro Tamiya ◽  
Akihiro Tamiya ◽  
Seigo Ishii ◽  
Katsuya Hirano ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cohort Study ◽  
Treatment Outcome ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Multicenter Cohort Study ◽  
Multicenter Cohort ◽  
Metastatic Sites

scholarly journals Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer – final results from the prospective German TLK cohort study

Lung Cancer ◽  
2017 ◽  
Vol 112 ◽  
pp. 216-224 ◽  
Author(s):  
Ulla von Verschuer ◽  
Roland Schnell ◽  
Hans Werner Tessen ◽  
Jochen Eggert ◽  
Adrian Binninger ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Cohort Study ◽  
Treatment Outcome ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

The impact of systemic treatment on brain metastasis in patients with non-small-cell lung cancer: A retrospective nationwide population-based cohort study.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e20572-e20572
Author(s):  
Yoon Ho Ko ◽  
Ji Hyung Hong ◽  
Der Sheng Sun ◽  
Hye Sung Won ◽  
Seok Yun Kang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cohort Study ◽  
Brain Metastasis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Cumulative Incidence ◽  
Systemic Treatment ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line

e20572 Background: We performed a large-scale, retrospective, nationwide, cohort study of the incidence of brain metastasis in patients with advanced non-small-cell lung cancer (NSCLC) according to the systemic treatment administered. Methods: The data were extracted from the Health Insurance Review and Assessment Service of Korea database from January 1, 2011 to November 30, 2016. Of the 29,224 patients newly diagnosed with stage IIIB or IV NSCLC who received first-line cytotoxic chemotherapy (CC group) or targeted therapy (TT group), 22,508 patients without brain metastasis were analyzed. Results: In total, 1,131 (5.0%) patients subsequently developed brain metastasis. The overall cumulative incidence of brain metastasis was significantly higher in the TT group than in the CC group (1-year cumulative incidence: 8.7 ± 0.6% vs. 3.8 ± 0.3%; 3-year: 17.2 ± 0.7% vs. 5.0 ± 0.3%, respectively; P < 0.001), despite the higher rate of brain metastasis in the CC group at < 3 years after diagnosis. Younger age, female sex, living in a rural area, anticoagulant use, and first-line TT (relative risk, 2.17 ± 0.03; 95% confidence interval, 1.92–2.50, P < 0.0001) retained significant associations with subsequent brain metastasis after adjusting for all variables. Conclusions: In the Korean population, the overall cumulative incidence of brain metastasis was significantly higher in patients in the TT group than in those in the CC group; the former could be regarded as having mutations in the EGFR or ALK gene.

Sign in / Sign up

Export Citation Format

Share Document